News NewsletterFeatured ArticlesNewsletter SubscribeEventsMedia Report from the Annual General Meeting of AroCell 19 May 2016 Report from the Annual General Meeting of AroCell EnglishKommuniké från årsstämman i AroCell Swedish CategoriesNewsPress ReleasesLatest postsBeslut vid årsstämman i AroCell AB (publ) 2017 18 May 2017AroCell AB (publ) Interim report for period 1 January – 31 March 2017 11 May 2017AroCell Presentation at 13th Annual Biomarkers & Immuno-Oncology World Congress 2017 in Philadelphia 19 April 2017KALLELSE TILL ÅRSSTÄMMA I AROCELL AB (PUBL) 13 April 2017AroCell TK 210 ELISA Webinar Recording is now available! 28 March 2017Archive2017Beslut vid årsstämman i AroCell AB (publ) 201718 May 2017AroCell AB (publ) Interim report for period 1 January – 31 March 201711 May 2017AroCell Presentation at 13th Annual Biomarkers & Immuno-Oncology World Congress 2017 in Philadelphia19 April 2017KALLELSE TILL ÅRSSTÄMMA I AROCELL AB (PUBL)13 April 2017AroCell TK 210 ELISA Webinar Recording is now available!28 March 2017AroCell AB (publ) Year-End Report16 February 2017AroCell research poster on prostate cancer has been accepted by American Association for Cancer Research (AARC)24 January 2017Nomination committee appointed for Annual General Meeting 201719 January 20172016Announcement – AroCell AB PR and Marketing Communications Manager19 December 2016Interim report January – September 201617 November 2016Ann Hammarstrand appointed as new CFO to AroCell 3 November 2016AroCell signs distribution agreement with Eagle Biosciences in the United States 6 October 2016New TK 210 ELISA product presentation 2 October 2016Oral presentation today of TK 210 ELISA abstract at ISOBM, Chicago 4 September 2016Interim report January – June 201625 August 2016Improved measurement of Thymidine Kinase 1 within the normal range due to improved composition of the zero calibrator.12 August 2016Nasdaq News Release 1 July 2016AroCell is approved for listing on the Nasdaq First North and publishes Corporate description28 June 2016AroCell applying for listing on the Nasdaq First North exchange21 June 2016Christine Tadgell new board member in AroCell23 May 2016CEO Jan Stålemark’s presentation at the AGM 201619 May 2016Report from the Annual General Meeting of AroCell19 May 2016AroCell Newsletter for May is now available11 May 2016Interim report January – March 201610 May 2016Leading profile in biomarkers joins the AroCell management team 2 May 2016New patent strengthens the AroCell patent portfolio28 April 2016Annual Report 201527 April 2016New clinical study with promising results for the TK 210 ELISA test from AroCell18 April 2016Kallelse till årsstämma i AroCell AB (publ)18 April 2016Final call for trading with BTA 8 January 20162015Nomination committee appointed for Annual General Meeting 201617 December 2015Oversubscription of preferential rights issue 8 December 2015Sign up for our Newsletter! 8 December 2015Presentation by CEO Jan Stålemark at Redeye Investor Forum, December 1 2 December 2015Interview with CEO Jan Stålemark for Analysguiden, November 201530 November 2015Presentation from Stora Aktiedagen Göteborg, November 2330 November 2015AroCell announces prospectus, teaser and application form17 November 2015Progress for development of prostate treatment, results from STHLM3 presented today10 November 2015AroCell announces interim report three will be brought forward 6 November 2015Announcement of fully guaranteed preferential rights issue of approximately 52.2 MSEK 6 November 2015Continued expansion to AroCell organization23 October 2015AroCell presents a robust TK1 blood-test at an international biomarker meeting19 October 2015Clarification regarding press release about CE marking 2 October 2015AroCell announces that it has filed for the CE-mark registration of TK 210 ELISA 1 October 2015AroCell announces achievement of critical milestone: successful phase 1 review of TK 210 ELISA production process.17 August 2015AroCell recognized by EU Commission and Horizon 2020 Program Committee13 August 2015AroCell strengthens the organization 5 June 2015Report from the annual general meeting of AroCell 3 June 2015Notice of annual general meeting of AroCell AB (publ) 6 May 2015Schedule revision providing for CE-mark during third quarter 201512 February 2015Revised schedule means CE-marking during the third quarter of 201512 February 20152014New clinical study with promising results29 October 2014
